NextCure seeks Delaware court order validating 2025 reverse stock split amendment

• NextCure filed a Delaware Chancery Court petition seeking validation of its 2025 reverse stock split charter amendment under DGCL Section 205.
• The filing targets uncertainty over whether the amendment required a 66 2/3% outstanding-share vote under its charter’s supermajority provision.
• Stockholders backed the proposal with 18,166,577 votes for vs 2,028,946 against; support totaled 64.76% of outstanding shares.
• The company implemented a 1-for-12 reverse split effective July 14, 2025, then completed financings and pursued a merger with Avere.
• It warned that unresolved validity questions could disrupt trading, impair the Avere business combination, and complicate its capital structure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-110971), on September 25, 2026, and is solely responsible for the information contained therein.